Table 5.
Pharmacokinetic studies of orally administered SCT, MCT, and LCT SNEDDS loaded with Chlorpromazine. Results are presented as mean ± SD of different experimental groups of rabbits (n = 5).
| Pharmacokinetic Parameter | Control | SCT | MCT | LCT |
|---|---|---|---|---|
| AUC 0 – t (µg/mL/h) | 87.400 ± 1.180 | 160.491 ± 2.368 | 253.419 ± 9.721 | 525.882 ± 10.815 |
| t1/2 (h) | 5.736 ± 0.312 | 6.195 ± 0.154 | 7.177 ± 0.094 | 9.876 ± 0.251 |
| Kd (h-1) | 0.121 ± 0.006 | 0.111 ± 0.002 | 0.096 ± 0.001 | 0.070 ± 0.008 |
| Ka (h-1) | 0.548 ± 0.172 | 1.166 ± 0.192 | 1.150 ± 0.290 | 0.633 ± 0.081 |
| Cmax (µg/mL) | 13.165 ± 1.454 | 21.595 ± 0.978 | 29.134 ± 1.62 | 48.642 ± 2.596 |
| Frel (%) | 6.6% | 12% | 19% | 40% |
AUC 0 – t plasma drug concentration over time interval 0-t h, t1/2 – half-life, Kd – drug disposition rate constant, Ka – absorption rate constant, Cmax – maximum serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose, Frel - relative bioavailability.